Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
Median progression free survival on olaparib was 16.2 months in relapsed ovarian cancer
Median progression free survival was 16.2 months with olaparib maintenance therapy in L-MOCA. Research teams now have outcome data for 224 treated participants in the single-arm study.
-
Mean BMI change was -6.7% on liraglutide in children with obesity at week 56
Mean BMI change at week 56 was -6.7% with liraglutide and 2.1% with placebo. Research teams now have main-phase outcome and safety data from a trial of 82 children aged 6 to below 12 years.
-
AmyriAD acquires AD04 Alzheimer's program from ADvantage
AmyriAD announced the acquisition of the AD04 program, a Phase 2b-ready investigational drug targeting neuroinflammation in mild Alzheimer's disease. The program was derived from a 332-patient Phase 2 vaccine study and is planned to enter Phase 2b development under the Innovative Licensing and Access Pathway.
-
New Phase 3 trials registered, week of November 16, 2026: 2 industry trials
Industry sponsors registered 2 Phase 3 trials on ClinicalTrials.gov so far in the week of November 16 to 22, 2026. They plan to enroll 10,120 participants in all; the largest, Novartis Pharmaceuticals' PINNACLE-MI trial, plans to enroll 10,000.
-
Phase 3 results posted, week of November 16, 2026: 3 industry trials
Industry sponsors posted results for 3 Phase 3 trials on ClinicalTrials.gov so far in the week of November 16 to 22, 2026. Together the trials enrolled 345 participants; the largest, AstraZeneca's L-MOCA trial, enrolled 225.
-
Dexa Medica Group registers completed Phase 3 trial of DLBS3233 in prediabetes
The study enrolled 120 participants and was first posted on ClinicalTrials.gov on November 16, 2026. It compared DLBS3233 at 100 mg and 200 mg once daily to Metformin XR 500 mg twice daily over a 12-week course of therapy.
-
Novartis registers Phase 3 trial of Pacibekitug in patients after a Myocardial Infarction
The study, PINNACLE-MI, plans to enroll 10,000 participants and aims to demonstrate superiority of Pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events in participants after a Myocardial Infarction. It is scheduled to start on November 30, 2026, with primary completion expected on October 22, 2030.
-
AstraZeneca posts results of L-MOCA olaparib maintenance trial
The company posted first results for its Phase 3 L-MOCA study, enrolling 225 participants who received olaparib 300mg tablets as maintenance therapy after platinum-based chemotherapy. The trial, which began on May 29, 2018, completed primary data collection on January 27, 2025.
-
Novo Nordisk posts results of Phase 3 dasiglucagon vs glucagon study in Asian adults with T1D
The study, completed with 38 participants, compared dasiglucagon and glucagon for treating severe hypoglycaemia in Asian adults with type 1 diabetes. Results were first posted on ClinicalTrials.gov on November 16, 2026.
-
Novo Nordisk posts results of Phase 3 liraglutide trial in children with obesity
Results for the 56-week, double-blind, randomized, placebo-controlled trial were first posted on ClinicalTrials.gov on November 16, 2026. The study enrolled 82 children aged 6 to below 12 years to evaluate the effect and safety of liraglutide 3.0 mg on weight management.
-
Roche Diagnostics makes Endotrophin research prototype assay available on cobas e801
The assay, a sandwich immunoassay, quantifies the intact 77-amino-acid Endotrophin hormone at Nordic Bioscience's CLIA lab. It has been measured in more than 50,000 patients with cardio-kidney-metabolic disease.
-
Aumseqa, Baxfendy, and Boehringer Ingelheim: the issue of November 9, 2026
The week of November 9 to 15, 2026: 60 briefs, 15 stories, led by Aumseqa, Baxfendy, and Boehringer Ingelheim.